Fundraising Fox

OncoImmune

Rockville, US · Delaware corporation · 2 known investors

First-in-class biologic drug targeting the CD24-Siglec innate immunity signaling pathway.

Biotech

Founders & leadership

PZ
Pan ZhengCo-founder
YL
Yang LiuCo-founder
MD
Martin DevenportNamed on SEC filing

Board

MH
Miao HongBoard director
KL
Karen LiuinBoard directorPartner at 3E Bioventures Capital
KG
Kun-Liang GuanBoard director
GF
Gary FangerBoard director

Investors · 2

3E Bioventures CapitalPalo Alto
HM Venture PartnersSan Francisco

Reported raises · per SEC filings

Form D private placements

$8.5M disclosed across 2 rounds · 2017–2020

▶$3MraisedMay 2020 · 3 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Yang LiuExecutive Officer, Director
  • Karen LiuDirector
  • Gary FangerDirector
  • Pan ZhengExecutive Officer
  • Kun-Liang GuanDirector
  • Martin DevenportExecutive Officer
  • Miao HongDirector
Offering amount
$3M
Amount sold
$3M
Minimum investment
$10K
Proceeds to insiders
$50K
First sale
Mar 2020
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$5.5MraisedFeb 2017 · 3 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Pan ZhengExecutive Officer
  • Kun-Liang GuanDirector
  • Miao HongDirector
  • Martin DevenportExecutive Officer
  • Yang LiuExecutive Officer, Director
  • Gary FangerDirector
  • Karen LiuDirector
Offering amount
$15M
Amount sold
$5.5M
Minimum investment
$100K
Proceeds to insiders
$100K
First sale
Jan 2017
Incorporated
Corporation, Ohio
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Non-dilutive funding · 9 SBIR/STTR awards

Federal grants — no equity taken
AgencyPhaseYearAmount
National Institutes of Health (NIH)National Institutes of HealthPhase I2020$400K
National Institutes of Health (NIH)National Institutes of HealthPhase I2020$396.7K
National Institutes of Health (NIH)National Institutes of HealthPhase II2019$3M
National Institutes of Health (NIH)National Institutes of HealthPhase ISTTR2019$312.7K
National Institutes of Health (NIH)National Institutes of HealthPhase I2019$212.7K
National Institutes of Health (NIH)National Institutes of HealthPhase II2017$2M
National Institutes of Health (NIH)National Institutes of HealthPhase I2014$395.4K
National Institutes of Health (NIH)National Institutes of HealthPhase I2011$155.2K
National Institutes of Health (NIH)National Institutes of HealthPhase I2011$150.2K

Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.

Frequently asked questions

What does OncoImmune do?
First-in-class biologic drug targeting the CD24-Siglec innate immunity signaling pathway.
Who founded OncoImmune?
OncoImmune was founded by Pan Zheng, Yang Liu.
Who are OncoImmune's investors?
OncoImmune's investors include 3E Bioventures Capital, HM Venture Partners.
How much funding has OncoImmune raised?
OncoImmune has disclosed $8.5M raised across 2 rounds.
Where is OncoImmune headquartered?
OncoImmune is headquartered in Rockville, US.